Literature DB >> 8693649

Renal oncocytoma: preoperative diagnosis using technetium 99m sestamibi imaging.

T S Gormley1, M J Van Every, A J Moreno.   

Abstract

OBJECTIVES: To determine if 99mTc-sestamibi (technetium 99m-methoxyisobutylisonitrile) can be used preoperatively to differentiate renal oncocytomas from other renal masses.
METHODS: We performed 99mTc-sestamibi scans on 6 patients with various renal masses, using a standard technique. The diagnosis in each patient was determined either by radiologic methods.
RESULTS: There was significantly increased uptake in the patient with the renal oncocytoma, whereas the other lesions had decreased uptake in comparison to normal kidney. This was determined visually and by mean pixel analysis.
CONCLUSIONS: Technetium 99m sestamibi scanning appears to have a potential role in the nonoperative diagnosis of renal oncocytomas, in combination with pathologic fine-needle biopsy confirmation. More definitive pathologic experience is required before recommending standard use.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8693649     DOI: 10.1016/s0090-4295(96)00095-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  10 in total

Review 1.  Nuclear imaging of renal tumours: a step towards improved risk stratification.

Authors:  Michael A Gorin; Steven P Rowe; Mohamad E Allaf
Journal:  Nat Rev Urol       Date:  2015-06-09       Impact factor: 14.432

Review 2.  A review of 99mTc-sestamibi SPECT/CT for renal oncocytomas: A modified diagnostic algorithm.

Authors:  Mitchell P Wilson; Prayash Katlariwala; Jonathan Abele; Gavin Low
Journal:  Intractable Rare Dis Res       Date:  2022-05

Review 3.  The value of sestamibi single-photon emission computed tomography/computed tomography in differentiating and staging renal cell carcinomas: A systematic review.

Authors:  Abdalla Ali Deb; Ayman Agag; Naufal Naushad; Rajbabu Krishnamoorthy; Hosam Serag
Journal:  Curr Urol       Date:  2022-02-17

Review 4.  Characterizing Indeterminate Renal Masses with Molecular Imaging: the Role of 99mTc-MIBI SPECT/CT.

Authors:  Andrew M Reynolds; Kristin Kelly Porter
Journal:  Curr Urol Rep       Date:  2017-09-12       Impact factor: 3.092

5.  Initial experience using 99mTc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma.

Authors:  Steven P Rowe; Michael A Gorin; Jennifer Gordetsky; Mark W Ball; Phillip M Pierorazio; Takahiro Higuchi; Jonathan I Epstein; Mohamad E Allaf; Mehrbod S Javadi
Journal:  Clin Nucl Med       Date:  2015-04       Impact factor: 7.794

6.  Characterization of indeterminate renal masses with molecular imaging: how do we turn potential into reality?

Authors:  Steven P Rowe; Mehrbod S Javadi; Mohamad E Allaf; Michael A Gorin
Journal:  EJNMMI Res       Date:  2017-04-12       Impact factor: 3.138

7.  Visual evaluation and differentiation of renal oncocytomas from renal cell carcinomas by means of 99mTc-sestamibi SPECT/CT.

Authors:  Antonios Tzortzakakis; Ove Gustafsson; Mattias Karlsson; Linnea Ekström-Ehn; Rammin Ghaffarpour; Rimma Axelsson
Journal:  EJNMMI Res       Date:  2017-03-29       Impact factor: 3.138

Review 8.  Renal Oncocytoma: The Diagnostic Challenge to Unmask the Double of Renal Cancer.

Authors:  Francesco Trevisani; Matteo Floris; Roberto Minnei; Alessandra Cinque
Journal:  Int J Mol Sci       Date:  2022-02-26       Impact factor: 5.923

Review 9.  Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives.

Authors:  Luca Urso; Angelo Castello; Giovanni Christian Rocca; Federica Lancia; Stefano Panareo; Corrado Cittanti; Licia Uccelli; Luigia Florimonte; Massimo Castellani; Carmelo Ippolito; Antonio Frassoldati; Mirco Bartolomei
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-25       Impact factor: 4.322

10.  Correlation of 99mTc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression.

Authors:  Steven P Rowe; Michael A Gorin; Lilja B Solnes; Mark W Ball; Ajuni Choudhary; Phillip M Pierorazio; Jonathan I Epstein; Mehrbod S Javadi; Mohamad E Allaf; Alex S Baras
Journal:  EJNMMI Res       Date:  2017-10-02       Impact factor: 3.138

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.